Tafinlar (Dabrafenib)
dabrafenib 50 mg capsule, 120 · ORAL · PBS code 14760W
AUTHORITY_REQUIREDWhat it costs
AU$4663.49 PBS-determined price per 240 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2025-04-01.
- • Repeats: 1.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Paediatric high grade glioma
Initial treatment
The condition must be World Health Organisation (WHO) grade 3 or 4; AND
The condition must be positive for a BRAF V600 mutation; AND
Patient must have either a: (i) Karnofsky, (ii) Lansky performance score of at least 50%; AND
Patient must have relapsed or progressed following frontline therapy; or
Patient must have failed to respond to frontline therapy; AND
Patient must be receiving PBS-subsidised trametinib and dabrafenib concomitantly for this condition; AND
Patient must have been aged between 12 months to 18 years at diagnosis.
Sponsor: Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.